A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer

British Journal of Cancer

Volumn 91, Issue 4, 2004, Pages 688-694

  Pavlenko, M ^a   Roos, A K ^a   Lundqvist, A ^a   Palmborg, A ^a   Miller, A M ^a   Ozenci, V ^a   Bergman, B ^b   Egevad, L ^b   Hellstrom M ^b   Kiessling, R ^a   Masucci, G ^b   Wersall P ^b   Nilsson, S ^b   Pisa, P ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

DNA vaccine; IFN gamma; Immune response; Immunotherapy; Prostate cancer; Prostate specific antigen

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; PLASMID VECTOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CASE REPORT; CELLULAR IMMUNITY; CLINICAL TRIAL; COHORT ANALYSIS; CYTOKINE PRODUCTION; DRUG SAFETY; EVALUATION; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; MALE; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; VACCINATION;

EID: 4344672484     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602019     Document Type: Article

References (33)

1. Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandstrom E, Wahren B (1998) Cellular cytotoxic response induced by DNA vaccination in HIV-1- infected patients. Lancet 351: 1320-1325
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer (published erratum appears in N Engl J Med 1991 Oct 31;325(18):1324) (see comments). N Engl J Med 324: 1156-1161
3. Chakraborty NG, Stevens RL, Mehrotra S, Laska E, Taxel P, Sporn JR, Schauer P, Albertsen PC (2003) Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother 52: 497-505
4. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY (1997) In vitro generation of human cytotoxic lymphocytes specific for peptides derived from prostate specific antigen. J Natl Cancer Inst 89: 293-300
5. Coulie PG, van der Bruggen P (2003) T-cell responses of vaccinated cancer patients. Curr Opin Immunol 15: 131-137
6. Diamandis EP, Yu H (1995) New biological functions of prostate-specific antigen? J Clin Endocrinol Metab 80: 1515-1517
7. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW (2000) A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6: 1632-1638
8. Freedland SJ, Pantuck AJ, Weider J, Zisman A, Belldegrun AS (2001) Immunotherapy of prostate cancer. Curr Urol Rep 2: 242-247
9. GLOBOCAN 2000 I.C.N. (2001) Cancer Incidence, Mortality and Prevalence Worldwide. Lyon: IARC Press
10. Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J (2002) Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53: 109-117
11. Heiser A, Coleman D, Dannull J, Yancey D, Maurice M, Lallas C, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109: 409-417
12. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB (2002) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25: 97-138
13. Kim JJ, Yang JS, Nottingham LK, Tang W, Dang K, Manson KH, Wyand MS, Wilson DM, Weiner DB (2001) Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen. Oncogene 20: 4497-4506
14. Klinman DM, Yamshchikov G, Ishigatsubo Y (1997) Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 158: 3635-3639
15. Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, Kumar S, Wang R, Doolan DL, Maguire JD, Parker SE, Hobart P, Norman J, Hoffman SL (2000) Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18: 1893-1901
16. Liu MA (2003) DNA vaccines: a review. J Intern Med 253: 402-410
17. Lollini PL, Forni G (2002) Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol Immunother 51: 409-416
18. Lundwall A, Lilja H (1987) Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 214: 317-322
19. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB (1998) First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178: 92-100
20. Meidenbauer N, Harris DT, Spitler LE, Whiteside TL (2000) Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 43: 88-100
21. Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT (2000) Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol 38: 208-217
22. Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S (2003) Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57: 80-92
23. Parmiani G, Rivoltini L, Andreola G, Carrabba M (2000) Cytokines in cancer therapy. Immunol Lett 74: 41-44
24. Riegman PH, Vlietstra RJ, van der Korput JA, Romijn JC, Trapman J (1989) Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem Biophys Res Commun 159: 95-102
25. Rini BI, Weinberg V, Bok R, Small EJ (2003) Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 21: 99-105
26. Roos A-K, Pavlenko M, Charo J, Egevad L, Pisa P (2004) Induction of PSA-specific CTLs anti-tumor immunity by a genetic prostate cancer vaccine. Prostate, (in press)
27. Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE (2003) Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 14: 709-714
28. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, Silverman GJ, Lotz M, Carson DA, Raz E (1996) Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273: 352-354
29. Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS (2003) Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 98: 144-154
30. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, van Beckhoven A, Levy R (2002) Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 62: 5845-5852
31. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Feigner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, Hawe LA, Leander KR, Martinez D, Perry HC, Shiver JW, Montgomery DL, Liu MA (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749
32. Velders MP, Schreiber H, Kast WM (1998) Active immunization against cancer cells: impediments and advances. Semin Oncol 25: 697-706
33. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, Jones TR, Hobart P, Margalith M, Ng J, Weiss WR, Sedegah M, de Taisne C, ANorman J, Hoffman SL (1998) Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282: 476-480